Biotech News

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

NEXGEL (NXGL)NEXGEL2026-03-12 12:45 ESTPartnership

NXGL (NXGL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is nxgl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

NEXGEL

Hydrogel and Healthcare Products Company NEXGEL develops, manufactures, and commercializes healthcare, beauty, and over-the-counter products. Its core expertise is in soft, high-water-content hydrogels used in wound care, skin care, consumer health, and other applications requiring gentle contact with the body. Cross-Linked Hydrogel...

Recent company news

NXGLNEXGEL2026-08-20 20:05 EST

NEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume Concentration

NXGLNEXGEL2026-05-13 12:30 EST

NEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX Surgical

Stock data

Close: 0.33 USD
Market cap: 5.31M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

Related news

NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE